ACUTE LEUKEMIAS XVIII
Biology and Treatment Strategies

Munich, Germany - March 19-22, 2023

International Symposium

S U N D A Y , March 19, 2023

EDUCATIONAL SYMPOSIUM of the AGIHO
(supported by a grant by GILEAD Sciences GmbH)
The Hematology Patient and the ICU

10.00-11.30
Interdisciplinary Educational Symposium

Arbeitsgemeinschaft Infektionen der DGHO (AGIHO)
(Infectious Diseases Working Party of the DGHO)
(Lecture Hall III/IV)

Co-Chairs:
D. Seidel, Cologne, DE
Ch. Rieger, Germering, DE

10.00-10.20
D. Teschner, Würzburg, DE

Current Anti-Infective Prophylaxis- and Therapeutic Strategies after Allogeneic Stem Cell Transplantation"

10.20-10.40
D. Seidel, Cologne, DE

Mucormykosis and Covid-19

10.40-11.00
Ch. Rieger, Germering, DE

Vaccinations in Patients with Hematological Malignancies

11.00-11.20
L. Pagano, Rome, I

Covid-19 and its Impact on Hematological Treatment Strategies

 

12.00-13.40 MS I:
Basic Biology in AML

Lecture Hall III
(Overflow Rooms: LHs IV+V)

Co-Chairs:
W.E. Fibbe, Leiden, NL
C. Müller-Tidow, Heidelberg, DE

12.00-12.20
Th. Oellerich, Frankfurt, DE

Drivers in AML

12.20-12.40
S. Armstrong, Boston, MA, USA

Targeting the Epigenetic Machinery in AML

12.40-13.00
P. van Galen, Boston, MA, USA

Genomics and Transcriptomics of Leukemia Evolution at
Single Cell Resolution".

13.00-13.20
D. Bonnet, London, UK

Mapping the Leukemia Microenvironment

13.20-13.40
C. Bonifer, Birmingham, UK

Understanding AML Development and Evolution through
Transcriptional Network Analysis

 

14.15-16.00 MS II:
Clonal Evolution and Leukemic Stem Cells

Lecture Hall III
(Overflow Rooms: LHs IV+V)

Co-Chairs:
K. Rouault-Pierre, London, UK
A. Trumpp, Heidelberg, DE

14.15-14.35
R. Majeti, Stanford, CA, USA

Pre-Leukemic Hematopoietic Stem Cells

14.35-14.55
L. Shlush, Rehovot, IL (tbc)

Origin of Mutations in Myeloid Neoplasia

14.55-15.15
I. Jeremias, Munich, DE

Functional Diversity in Leukemic Stem Cells

15.15-15.35
J. Tyner, Chicago, IL, USA

Functional Genomics to Understand Tumor Intrinsic and
Microenvironmental Mechanisms of Myeloid Leukemia

15.35-15.55
C. Lengerke, Tübingen, DE

Immune Escape in AML Stem Cells

 

M O N D A Y , March 20, 2023

08:30-09:45
OPENING SESSION – ISALXVIII

08:30-08:45
WELCOME ADDRESS

W. Hiddemann, Munich, DE
Symposium Chairman
Lecture Hall III
(Overflow Rooms: LHs IV+V)

08:45-09:45
THOMAS-BÜCHNER LECTURE

Lecture Hall III
(Overflow Rooms: LHs IV+V)

Introduction
G. Ossenkoppele, Amsterdam, NL

B. Ebert, Boston, MA, USA
Clonal Evolution in AML

 

10:15-11:55 MS III:
Genetic and Molecular Characterization of AML:

Novel Markers for Diagnosis and Prognosis
Lecture Hall III
(Overflow Rooms: LHs IV+V)

Co-Chairs:
G. Ossenkoppele, Amsterdam, NL
F. Thol, Hannover, DE

10:15-10:35
L. Godley, Chicago, IL, USA

Significance of Preleukemic Clones

10:35-10:55
J.J. Schuringa, Groningen, NL

Dissecting Heterogeneity in AML and the Niche

10:55-11:15
K. Tzelepis, Cambridge, UK

The Role of RNA Modifications in Mye3loid Leukaemogenesis

11:15-11:35
K. Metzeler, Leipzig, DE

Clonal Hematopoiesis after AML Treatment

11:35-11:55
M. Andreeff, Houston, TX, USA

Novel Mitochondrial Targets in AML

 

14:00-15:40 MS IV:
Novel Approaches and Targeted Therapies in AML

Lecture Hall III
(Overflow Rooms LHs IV+V)

Co-Chairs:
B. Löwenberg, Rotterdam, NL
H. Serve, Frankfurt, DE

14:00-14:20
St. De Botton, Villejuif, F

RARA-positive AML is a Novel Patient Subset with an Actionable Target for Treatment with SY-1425, an Oral, Selective RARα Antagonist

14:20-14:40
M.L. Levis, Baltimore, MD, USA

Targeting FLT3

14:40-15:00
C. DiNardo, Houston, TX, USA

The Utility of BCL2 Inhibition in AML

15:00-15:20
M. Konopleva, Houston, TX, USA

Novel Combination Therapies in AML

15:20-15:40
K. Spiekermann, Munich, DE

Therapy Resistance in AML

 

16:00-18:00 MS V (a):
ON-SITE Poster Viewing and Discussion Session

(Posters will be presented on the Upper Floor of the symposium venue.
A cheese and wine tasting is organized, where a great variety of Bavarian cheese will be served).

All poster presenters are expected to participate in MS V (a) to allow all participants and members of the jury to talk to the presenters and have a personal scientific exchange about their poster(s).

MS V (b): Additional INTERACTIVE virtual Poster Viewing and Discussion Session for virtual participants
Tuesday, March 21, 2023, between 16:00 and 18:00: for details see page 28 of this program

 

T U E S D A Y, March 21, 2023

10:50-12:30 MS VII:
Current Therapeutic Strategies in AML and APL

Lecture Hall III
(Overflow Rooms LHs IV+V)

Co-Chairs:
A. Burnett, Isle of Arean, UK
U. Platzbecker, Leipzig, DE

10:50-11:10
K. Döhner, Ulm, DE

Current AMLSG Trials

11:10-11:30
P. Montesinos, Valencia, E

The PETHEMA Experience in APL

11:30-11:50
Ch. Röllig, Dresden, DE

Combining Treatment Optimization with Novel Agents:
The SAL Trial Portfolio

11:50-12:10
G.J. Roboz, New York, NY, USA

Non-Transplant Post-Remission Strategies in AML

12:10-12:30
N.H. Russell, Nottingham, UK

Lessons from MRC Strategies in AML

 

14:00-15:40 MS VIII:
Relevance of MRD in Acute Leukemias

Lecture Hall III
(Overflow Rooms LHs IV+V)

Co-Chairs:
H. Dombret, Paris, F
C. Baldus, Kiel, DE

14:00-14:20
Ch. Hourigan, Bethesda, MA, USA

Clinical Use of MRD in AML

14:20-14:40
J. Cloos, Amsterdam, NL

Impact of Oligoclonality on Accurate MRD Assessment in AML

14:40-15:00
M. Heuser, Hannover, DE

NGS-Based MRD Measurement in AML

15:00-15:20
A. Venditti, Rome, I

MRD-Guided Therapy Strategies in AML

15:20-15:40
R. Walter, Seattle, WA, USA

Is MRD Monitoring in AML Really Helpful?

 

16:00-17:25 MS IX:
Festive Award Ceremony and Presentations

Lecture Hall VI

Co-Chairs:
K. Götze, Munich, DE
J.H. Klusmann, Halle, DE

16:00-16:10
Poster Prize Announcement and Presentation of Certificates:

Official Announcement and Presentation of Certificates of the
2 ISALXVIII Poster Prize Winners

16.10-16.20
3 Best of Free Contributions: Announcement of Award

Winners, Presentation of Certificates and Talks:
Official Announcement of this Year's 3 Best of Free
Contributions' Winners followed by a 10 minutes' presentation

16.20-16.30
Best of Free Contributions Talk 1: R. Palmieri, Rome, I, Poster # 46

16.30-16.40
Best of Free Contributions Talk 2: J. Müller, Zurich, CH, Poster # 67

16.40-16:50
Best of Free Contributions Talk 3: T. Stopka, Prague, CZ, Poster # 72

16:50-16:55
José Carreras Leukemia Clinical Research Award 2023 (JCLCRA):

Official Announcement of the JCLCRA 2023 Laureate followed by a 15
minutes' presentation

16:55-17:15
JCLCRA 2023 Laureate Talk

17:15-17:25
Awarding of the José Carreras GPOH Doctoral Scholarship 2023

 

17:30-18:15 MS V (b):
INTERACTIVE virtual Poster Viewing and

Discussion Session for online participants
Virtual WONDER Rooms

 

W E D N E S D A Y , March 22, 2023

08:30-10:30 MS X:
Immunotherapy for Acute Leukemias

Lecture Hall III
(Overflow Rooms LHs IV+V)

Co-Chairs:
M. Manz, Zurich, CH
M. von Bergwelt, Munich, DE

08:30-08:50
J. DiPersio, St. Louis, MO, USA

Off-the-Shelf Cellular Therapies for T-Cell Malignancies

08:50-09:10
Ch. Craddock, Birmingham, UK

New Transplant Strategies in AML

09:10-09:30
R. Zeiser, Freiburg, DE

Mechanisms of Relapse after AlloSCT

09:30-09:50
S. Gill, Philadelphia, PA, USA

CAR-T Cells in AML Therapy

09:50-10:10
L. Vago, Milano, I

Immune Escape in AML

10:10-10:30 M. Subklewe, Munich, DE
T-Cell Bi-Specifics in AL

 

11:00-12:40 MS XI:
Biology and Treatment Strategies of ALL

Lecture Hall III
(Overflow Rooms LHs IV+V)

Co-Chairs:
H. Greinix, Graz, A
D. Hoelzer, Frankfurt, DE

11:00-11:20
N. Gökbuget, Frankfurt, DE

Risk-Adapted Therapy of ALL

11:20-11:40
R. Foa, Rome, I

Chemotheraepy-Free Therapy of ALL

11:40-12:00
A. Fielding, London, UK

NCRI Trials in ALL

12:00-12:20
F. Ravandi, Houston, TX, USA

ALL Approach at MD Anderson in 2022

12:20-12:40
M. Müschen, New Haven, CT, USA

Mechanisms of Central Tolerance as Therapeutic
Targets in B-ALL